Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Revive Therapeutics

Next Previous
Drug Profile

Psilocybin - Revive Therapeutics

Alternative Names: Psilocybine - Revive Therapeutics; PSY-0.1; PSY-0.2; PSY-0.3; PSY-0.4/0.5; PSY-0.6

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Psilocin Pharma Corp
  • Developer PharmaTher; Psilocin Pharma Corp; Revive Therapeutics; University of Wisconsin-Madison
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Substance-related disorders
  • Preclinical Neurological disorders; Opioid-related disorders; Psychiatric disorders; Traumatic brain injuries
  • Research Cancer; Unspecified
  • No development reported Anxiety disorders; Bipolar disorders; Depressive disorders; Eating disorders

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for research development in Anxiety-disorders in Canada (Buccal, Film)
  • 28 Mar 2024 No recent reports of development identified for research development in Anxiety-disorders in Canada (PO, Capsule)
  • 28 Mar 2024 No recent reports of development identified for research development in Anxiety-disorders in Canada (Sublingual, Film)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top